Former SpaceX engineers launch Synthego, CRISPRevolution to accelerate genome engineering research

NewsGuard 100/100 Score

Former SpaceX engineers release CRISPRevolution to accelerate low cost biological research with rapid, high quality genome editing

Synthego, a leading provider of genome engineering solutions, officially launches today. Synthego’s flagship product line, CRISPRevolution, features synthetic guide RNA products designed to accelerate CRISPR/Cas9 and Cpf1 genome engineering research. CRISPRevolution is the first product line to offer economical access to fully synthetic RNA for high fidelity editing and increased precision in genome editing.

Former SpaceX engineers Paul Dabrowski and Michael Dabrowski founded Synthego after identifying an opportunity to significantly improve how biological research is conducted. Synthego is focused on removing longstanding research challenges, such as reagent quality, precision liquid handling, access to tools, and lack of repeatability and scalability that often interfere with a biological researchers’ ability to control experiments.

“Our primary goal with Synthego is to break through the barriers to entry for world-class quality life science research by applying next-generation automation processes and engineering principles,” said Paul Dabrowski, CEO of Synthego. “Synthego is the merger of biology and engineering to create a well-oiled genome engineering solutions company. Our platform minimizes the variables and risks in biological research by automating workflows, controlling quality, scaling for massive experiments and reducing cost structures.”

The Synthego Approach

Synthego minimizes the variables and risks in biological research by automating workflows, precisely controlling quality at each step, scaling for massive experiments, and reducing cost structures. To accomplish this, Synthego has built a team consisting of science, technology, engineering and mathematics (STEM) disciplines, operations and manufacturing talent, and industry professionals. Its first commercial product is aimed at perfecting the rapidly expanding science around CRISPR genome engineering and research.

“Synthego’s synthetic RNA for CRISPR is a huge time saver,” said Erin Jarvis, PhD candidate, Evolutionary Developmental Biology, UC Berkeley (Patel Lab). “I was injecting crustacean embryos within one hour of receiving the RNA from Synthego. My lab mate, meanwhile, still had a long night of PCR, IVT, and RNA purification ahead of him."

CRISPRevolution Development

A direct result of Synthego’s automated platform is the development of CRISPRevolution - a portfolio of synthetic guide RNA products for CRISPR genome editing. CRISPRevolution democratizes genome engineering tools for researchers, increasing the adoption of CRISPR techniques by offering a high quality, low-cost product with fast turnaround that every scientist needs in order to accurately and successfully conduct genome editing experiments.

Applications that require 100 percent DNA-free, high quality guide RNA are enabled with CRISPRevolution. These applications include gene therapy, agriculture, biotech research, drug development and CRISPR therapeutics.

CRISPRevolution Benefits:

  • Up to 90 percent gene knockout efficiency
  • Up to 4 times faster transfection readiness vs. other genome engineering techniques
  • Up to 80 percent lower cost compared to other synthetic RNA products
  • Ready for high-throughput screening and applications
  • 100 percent DNA-free

“We have just scratched the surface of what’s possible with CRISPR,” said Scott Nolan, partner at Founders Fund and Synthego investor. “This technology will impact everything from therapeutics to agriculture to materials science, and Synthego is the only company prepared to meet the growing demand for synthetic RNA across all of these industries.”



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Increased emotional sensitivity linked to previous COVID-19 infection, new research suggests